Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced an Ebola virus outbreak in the...

Merck & Co. Inc. (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) said they are ready to make their respective Ebola vaccines available to the World Health Organization (WHO), which announced Tuesday an Ebola virus outbreak in...

Aethlon said it submitted a Humanitarian Use Device (HUD) application to FDA for Aethlon Hemopurifier to treat Ebola virus infection. The product is an extracorporeal device that selectively absorbs viruses and immunosuppressive toxins from blood....

Data from 10 evaluable patients with HCV infection in the Indian Extract-1 trial showed that treatment with Hemopurifier therapy during the first 3 days of a 48-week treatment regimen with SOC (peginterferon and ribavirin) led...

Aethlon said it received updated guidance from FDA that the company can provide Hemopurifier to treat Ebola infection in the U.S. through expanded access “emergency use” provisions, which is an expansion of the previous guidance...

Aethlon will provide its Hemopurifier under a compassionate use program in the U.S. to treat Ebola infection. Aethlon plans to start a U.S. feasibility study this month to evaluate the device for chronic viral pathogens,...

Next month, Aethlon said it will begin a U.S. feasibility study to evaluate its Hemopurifier for chronic viral pathogens, such as HIV and HCV infection, and pandemic threats, including Ebola. The company also announced a...

Preliminary data from the first 9 patients with HCV genotype 1 infection in the Indian Extract-1 study showed that treatment with Hemopurifier therapy during the first 3 days of SOC (peginterferon and ribavirin) led to...